An interventional study of Protein intake 1.2 g/kg/day and resistance exercise and Protein intake 1.0 g/kg/day and resistance exercise in Sarcopenia and Chronic Kidney Disease, sponsored by Chulalongkorn University. Enrolling by invitation at 1 site in Thailand. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-08-11.
Sponsored by Chulalongkorn University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Sarcopenia with a site in Thailand — 6 open to participants now, 6 under way, 1 of them phase 3. Sarcopenia · Thailand.
Among the 12 studies in Sarcopenia with a site in Thailand, this one is the only one that started in 2025, is one of 6 with no phase, and was the 10th registered.
1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →6 of the 12 studies in Sarcopenia with a site in Thailand are open now. Recruiting first, the newest first:
Prince of Songkla University · Sites in Thailand
Ages 18+ · Healthy volunteers
Mahidol University · Sites in Thailand
Ages 18–75
Mahidol University · Sites in Thailand
Ages 18–85
Abbott Nutrition · Sites in Thailand
Ages 55–99
Siriraj Hospital · Sites in Thailand
Ages 60–90
A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 60 across 860 interventional studies indexed under Sarcopenia.
Median enrollment 65 across the 8 interventional studies, 202 across the 4 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 12 have an industry lead sponsor. The 7 most frequent:
Chulalongkorn University is the lead sponsor of 323 studies on the registry; 67 are open to participants now.
Chulalongkorn University has 2 studies filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Sarcopenia with a site in Thailand, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to determine whether increasing protein intake in elderly adults with pre-dialysis chronic kidney disease, in combination with resistance exercise, improves muscle mass without worsening renal function.The main questions it aims to answer are:
Researchers will compare a group assigned to intake 1.2 g/kg BW/day of protein with another group assigned to intake 1.0 g/kg BW/day, to assess whether the higher intake improves muscle mass and physical performance without causing harm.
Participants will
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: Protein intake 1.2 g/kg/day and resistance exercise
Behavioral: Protein intake 1.0 g/kg/day and resistance exercise
Protein intake of 1.2 g/kg/day in combination with resistance exercise using resistance bands
Protein intake 1.0 g/kg/day in combination with resistance exercise using resistance bands
Between-Group Differences in Muscle Mass Changes at 6 Months
Time frame: From enrollment to the end of intervention at 24 weeks
Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.
Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 12 months is below that.
Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.